Regulatory landscape for biosimilars in Latin America is uneven

04/10/2013 | PMLive.com (U.K.)

Economic growth in Latin America has increased the demand for and access to health care services, and government expenditures have risen accordingly, according to World Health Organization data. As complex biologic drugs account for an increasing proportion of spending, payers are looking to biosimilar drugs to contain costs. Despite the pressure, few countries have a clear pathway to biosimilars development and most are approaching the issue with caution.

View Full Article in:

PMLive.com (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care